share_log

Predictmedix AI Achieves Significant Milestones in Mental Health Detection and Analysis

Predictmedix AI Achieves Significant Milestones in Mental Health Detection and Analysis

Predictmedix AI 在心理健康检测和分析方面取得重要里程碑
Accesswire ·  2023/12/05 07:30

TORONTO, ON / ACCESSWIRE / December 5, 2023 / Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) (the "Company" or "Predictmedix"), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI) is proud to announce ground-breaking achievements in the realm of mental health detection and analysis. With a commitment to advancing healthcare through innovative AI solutions, Predictmedix AI has successfully developed functionalities to detect depression, anxiety, and analyze individual mood and emotions.

安大略省多伦多/ACCESSWIRE/2023年12月5日/由专有人工智能(AI)提供支持的快速健康筛查解决方案的领先提供商Predictmedix AI Inc.(CSE: PMED)(OTCQB: PMED)(FRA: 3QP)(“公司” 或 “Predictmedix”)自豪地宣布在心理健康检测和分析领域取得开创性成就。Predictmedix AI致力于通过创新的人工智能解决方案推动医疗保健发展,成功开发了检测抑郁、焦虑以及分析个人情绪和情绪的功能。

Statistics from Forbes Health1 reveal a staggering reality: an estimated 5% of adults worldwide grapple with depression, a figure potentially overshadowed by underreporting and undiagnosed cases, suggesting an even more pervasive mental health crisis. These alarming statistics underscore the critical need for proactive measures to address mental health challenges. In response, Predictmedix AI's cutting-edge technologies aim to revolutionize mental health care. The focus on early detection and nuanced analysis stands as a beacon of hope in the face of this escalating global mental health landscape. By harnessing the power of AI, Predictmedix AI aspires not just to identify but to intervene early, potentially reshaping outcomes and offering support to those silently battling mental health issues.

来自福布斯健康的统计数据1 揭示了一个惊人的现实:全球估计有5%的成年人患有抑郁症,这一数字可能被报告不足和未确诊的病例所掩盖,这表明心理健康危机更加普遍。这些令人震惊的统计数据突出表明,迫切需要采取积极措施来应对心理健康挑战。作为回应,Predictmedix AI的尖端技术旨在彻底改变心理保健。面对不断升级的全球心理健康格局,对早期发现和细致分析的关注是希望的灯塔。通过利用人工智能的力量,Predictmedix AI不仅希望进行识别,还希望尽早进行干预,从而有可能重塑结果,并为那些默默地与心理健康问题作斗争的人提供支持。

Key Accomplishments:

主要成就:

  • Depression and Anxiety Detection: Predictmedix AI has developed advanced functionality to detect signs of depression and anxiety through its state-of-the-art AI algorithms. This remarkable capability addresses the critical need for early identification and intervention in mental health.
  • Mood and Emotion Analysis: The company has successfully implemented functionalities to detect and analyze individual mood and emotions. This technology offers a comprehensive understanding of an individual's mental well-being, going beyond traditional diagnostics.
  • Significant Scan Milestone: Predictmedix AI proudly announces the completion of over 250,000 individual scans. This milestone underscores the effectiveness and reliability of the AI-powered Safe Entry Station technology. Machine learning accuracy continues to improve across healthcare and other industries, positioning Predictmedix AI as a leader in the evolving landscape of health and safety applications.
  • 抑郁和焦虑检测:Predictmedix AI开发了高级功能,可通过其最先进的人工智能算法检测抑郁和焦虑的迹象。这种非凡的能力满足了早期发现和干预心理健康的迫切需求。
  • 情绪和情感分析:该公司已成功实现检测和分析个人情绪和情绪的功能。这项技术可以全面了解个人的心理健康,而不仅仅是传统诊断。
  • 重要的扫描里程碑:Predictmedix AI自豪地宣布已完成超过25万次个人扫描。这一里程碑凸显了人工智能驱动的安全入口站技术的有效性和可靠性。医疗保健和其他行业的机器学习准确性持续提高,使Predictmedix AI成为不断变化的健康和安全应用领域的领导者。

"Our achievements in developing advanced functionalities for depression and anxiety detection, coupled with mood and emotion analysis, mark a significant step forward in leveraging AI for mental health. The culminationof over 250,000 individual scans is a testament to the real-world impact of our technology. This milestone isn't merely a numerical achievement; it echoes the lives touched and the potential for early interventions that can reshape the course of mental health outcomes. As machine learning accuracy continues to improve, we are dedicated to advancing innovation in health and safety applications for the benefit of individuals and communities," commented Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix AI.

“我们在开发抑郁和焦虑检测的高级功能以及情绪和情感分析方面取得的成就,标志着在利用人工智能促进心理健康方面向前迈出了重要一步。超过 250,000 次单次扫描的结果证明了我们技术对现实世界的影响。这一里程碑不仅仅是一项数字成就;它呼应了所感动的生活以及早期干预措施可以重塑心理健康结果的潜力。随着机器学习准确性的不断提高,我们致力于推进健康和安全应用的创新,以造福个人和社区。” Predictmedix AI首席运营官Rahul Kushwah博士评论道。

To receive company news, please sign up for alerts at the bottom of the page link below:

要接收公司新闻,请在页面底部注册接收提醒,链接如下:

1

1

About Predictmedix AI Inc.

关于 Predictmedix AI Inc.

Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn.

Predictmedix AI Inc.(CSE: PMED)(OTCQB: PMED)(FRA: 3QP)是全球快速健康筛查和远程患者护理解决方案的新兴提供商。该公司的安全入口站由专有的人工智能(AI)提供支持,使用多光谱摄像机分析生理数据模式并预测各种健康问题,包括19种生理重要参数、药物或酒精损伤、疲劳或各种精神疾病。Predictmedix AI专有的远程患者护理平台为医疗专业人员提供了一套基于人工智能的工具,以改善患者的健康状况。要了解更多信息,请访问我们的网站 或者关注我们 推特Instagram 要么 领英

Public Relations Contact

公共关系联系人

For further media information or to set up an interview, please contact:

欲了解更多媒体信息或安排采访,请联系:

Nelson Hudes
Communications International (905) 660 9155
Nelson@hudescommunications.com
Dr. Rahul Kushwah (647) 889 6916

纳尔逊·哈德斯
通信国际 (905) 660 9155
Nelson@hudescommunications.com
Rahul Kushwah 博士 (647) 889 6916

Caution Regarding Forward-Looking Information:

关于前瞻性信息的注意事项:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

本新闻稿可能包含前瞻性陈述和基于当前预期的信息。这些陈述不应被视为对公司未来业绩或业绩的保证。此类陈述涉及已知和未知的风险、不确定性和其他因素,这些因素可能导致实际业绩、业绩或成就与此类陈述所暗示的结果存在重大差异。尽管此类陈述基于管理层的合理假设,但无法保证此类假设会被证明是正确的。我们不负责更新或修改它们以反映新的事件或情况。公司的证券尚未根据经修订的1933年《美国证券法》(“美国证券法”)或适用的州证券法进行注册,如果没有注册或不受此类注册要求的适用豁免,则不得向在美国的人或 “美国个人”(该术语的定义见美国证券法的法规)发行或出售,也不得为他们的账户或利益发行或出售。本新闻稿不构成出售要约或招揽买入要约,也不得在美国或任何此类要约、招揽或出售非法的司法管辖区出售证券。此外,还有一些已知和未知的风险因素可能导致公司的实际业绩、业绩或成就与本文件所含前瞻性信息所表达或暗示的未来业绩、业绩或成就存在重大差异,例如但不限于依赖获得监管部门批准;获得与其技术相关的知识产权的能力;运营历史有限;一般商业、经济、竞争、政治、监管和社会不确定性,以及特别是与 COVID-19 相关的不确定性;与公司无法控制的因素相关的风险,包括与 COVID-19 相关的风险;与公司股票相关的风险,包括该方可能也可能无法控制的事件导致的价格波动;对管理层的依赖;以及该行业其他竞争对手的紧急情况。

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

本文中的所有前瞻性信息均受本警示声明的全面限制,除非法律要求,否则公司不承担任何修改或更新任何此类前瞻性信息或公开宣布为反映未来业绩、事件或发展而对本文包含的任何前瞻性信息进行任何修订的结果的义务。

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

免责声明:“公司目前并未明确或暗示其产品有能力诊断、消除、治愈或遏制 COVID-19(或 SARS-2 冠状病毒)。

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

加拿大证券交易所尚未审查本新闻稿的充分性或准确性,也不承担任何责任。

SOURCE: Predictmedix AI Inc.

来源:Predictmedix AI Inc.


View source version on accesswire.com:
在 accesswire.com 上查看源代码版本:

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发